Skip to main content
NCBI home page
The Yale Journal of Biology and Medicine logoLink to The Yale Journal of Biology and Medicine
. 1990 Nov-Dec;63(6):565–579.

Evolving concepts of the epidemiology, diagnosis, and therapy of Mycobacterium tuberculosis infection.

J E Schweinle 1
PMCID: PMC2589394  PMID: 2092414

Abstract

Tuberculosis in the United States is evolving in nearly all respects--epidemiology, diagnosis, treatment, and prophylaxis. Today a relatively larger segment of the population has predisposing factors to infection with tuberculosis. There is a greater percentage of people who are elderly, who have immigrated from countries endemic for tuberculosis, or who are immunosuppressed due to medications necessary for other conditions, because of malignancies, or because of infection with HIV. Skin test classifications have been revised to give different meanings to different-sized areas of induration at the injection site for defined populations. More sensitive, more specific, and faster diagnostic laboratory tests for tuberculosis are being developed. Short-course chemotherapy of from six to nine months is now accepted as standard treatment, regardless of exactly which of the proven regimens of antibiotics or accepted lengths of therapy is used. Patient compliance is improved with the shorter courses both for treatment and for prophylaxis. Better compliance with therapy results in better treatment outcomes of infections with Mycobacterium tuberculosis.

Full text

PDF
565

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brown A. E., Holzer T. J., Andersen B. R. Capacity of human neutrophils to kill Mycobacterium tuberculosis. J Infect Dis. 1987 Dec;156(6):985–989. doi: 10.1093/infdis/156.6.985. [DOI] [PubMed] [Google Scholar]
  2. Centers for Disease Control (CDC) Diagnosis and management of mycobacterial infection and disease in persons with human T-lymphotropic virus type III/lymphadenopathy-associated virus infection. MMWR Morb Mortal Wkly Rep. 1986 Jul 18;35(28):448–452. [PubMed] [Google Scholar]
  3. Chaisson R. E., Schecter G. F., Theuer C. P., Rutherford G. W., Echenberg D. F., Hopewell P. C. Tuberculosis in patients with the acquired immunodeficiency syndrome. Clinical features, response to therapy, and survival. Am Rev Respir Dis. 1987 Sep;136(3):570–574. doi: 10.1164/ajrccm/136.3.570. [DOI] [PubMed] [Google Scholar]
  4. Clumeck N., Sonnet J., Taelman H., Mascart-Lemone F., De Bruyere M., Vandeperre P., Dasnoy J., Marcelis L., Lamy M., Jonas C. Acquired immunodeficiency syndrome in African patients. N Engl J Med. 1984 Feb 23;310(8):492–497. doi: 10.1056/NEJM198402233100804. [DOI] [PubMed] [Google Scholar]
  5. Cohn D. L., Catlin B. J., Peterson K. L., Judson F. N., Sbarbaro J. A. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen. Ann Intern Med. 1990 Mar 15;112(6):407–415. doi: 10.7326/0003-4819-76-3-112-6-407. [DOI] [PubMed] [Google Scholar]
  6. Combs D. L., O'Brien R. J., Geiter L. J. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med. 1990 Mar 15;112(6):397–406. doi: 10.7326/0003-4819-76-3-112-6-397. [DOI] [PubMed] [Google Scholar]
  7. Comstock G. W. New data on preventive treatment with isoniazid. Ann Intern Med. 1983 May;98(5 Pt 1):663–665. doi: 10.7326/0003-4819-98-5-663. [DOI] [PubMed] [Google Scholar]
  8. Cook G. C. Tuberculosis--certainly not a disease of the past! Q J Med. 1985 Sep;56(221):519–521. [PubMed] [Google Scholar]
  9. Crowle A. J., Elkins N. Relative permissiveness of macrophages from black and white people for virulent tubercle bacilli. Infect Immun. 1990 Mar;58(3):632–638. doi: 10.1128/iai.58.3.632-638.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Daniel T. M., Debanne S. M. The serodiagnosis of tuberculosis and other mycobacterial diseases by enzyme-linked immunosorbent assay. Am Rev Respir Dis. 1987 May;135(5):1137–1151. doi: 10.1164/arrd.1987.135.5.1137. [DOI] [PubMed] [Google Scholar]
  11. Daniel T. M. New approaches to the rapid diagnosis of tuberculous meningitis. J Infect Dis. 1987 Apr;155(4):599–602. doi: 10.1093/infdis/155.4.599. [DOI] [PubMed] [Google Scholar]
  12. Dutt A. K., Moers D., Stead W. W. Short-course chemotherapy for extrapulmonary tuberculosis. Nine years' experience. Ann Intern Med. 1986 Jan;104(1):7–12. doi: 10.7326/0003-4819-104-1-7. [DOI] [PubMed] [Google Scholar]
  13. Dutt A. K., Moers D., Stead W. W. Short-course chemotherapy for tuberculosis with mainly twice-weekly isoniazid and rifampin. Community physicians' seven-year experience with mainly outpatients. Am J Med. 1984 Aug;77(2):233–242. doi: 10.1016/0002-9343(84)90697-1. [DOI] [PubMed] [Google Scholar]
  14. Dutt A. K., Stead W. W. Present chemotherapy for tuberculosis. J Infect Dis. 1982 Nov;146(5):698–704. doi: 10.1093/infdis/146.5.698. [DOI] [PubMed] [Google Scholar]
  15. Eisenach K. D., Cave M. D., Bates J. H., Crawford J. T. Polymerase chain reaction amplification of a repetitive DNA sequence specific for Mycobacterium tuberculosis. J Infect Dis. 1990 May;161(5):977–981. doi: 10.1093/infdis/161.5.977. [DOI] [PubMed] [Google Scholar]
  16. French G. L., Chan C. Y., Cheung S. W., Oo K. T. Diagnosis of pulmonary tuberculosis by detection of tuberculostearic acid in sputum by using gas chromatography-mass spectrometry with selected ion monitoring. J Infect Dis. 1987 Aug;156(2):356–362. doi: 10.1093/infdis/156.2.356. [DOI] [PubMed] [Google Scholar]
  17. Glassroth J., Robins A. G., Snider D. E., Jr Tuberculosis in the 1980s. N Engl J Med. 1980 Jun 26;302(26):1441–1450. doi: 10.1056/NEJM198006263022603. [DOI] [PubMed] [Google Scholar]
  18. Grzybowski S. Tuberculosis control. The end of an era? Chest. 1983 Aug;84(2):123–125. doi: 10.1378/chest.84.2.123. [DOI] [PubMed] [Google Scholar]
  19. Kearns T. J., Russo P. K. The control and eradication of tuberculosis. A summary report. N Engl J Med. 1980 Oct 2;303(14):812–814. doi: 10.1056/NEJM198010023031411. [DOI] [PubMed] [Google Scholar]
  20. Moulder J. W. Comparative biology of intracellular parasitism. Microbiol Rev. 1985 Sep;49(3):298–337. doi: 10.1128/mr.49.3.298-337.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Pitchenik A. E., Cole C., Russell B. W., Fischl M. A., Spira T. J., Snider D. E., Jr Tuberculosis, atypical mycobacteriosis, and the acquired immunodeficiency syndrome among Haitian and non-Haitian patients in south Florida. Ann Intern Med. 1984 Nov;101(5):641–645. doi: 10.7326/0003-4819-101-5-641. [DOI] [PubMed] [Google Scholar]
  22. Rieder H. L., Cauthen G. M., Kelly G. D., Bloch A. B., Snider D. E., Jr Tuberculosis in the United States. JAMA. 1989 Jul 21;262(3):385–389. [PubMed] [Google Scholar]
  23. Schlesinger L. S., Bellinger-Kawahara C. G., Payne N. R., Horwitz M. A. Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3. J Immunol. 1990 Apr 1;144(7):2771–2780. [PubMed] [Google Scholar]
  24. Selwyn P. A., Hartel D., Lewis V. A., Schoenbaum E. E., Vermund S. H., Klein R. S., Walker A. T., Friedland G. H. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989 Mar 2;320(9):545–550. doi: 10.1056/NEJM198903023200901. [DOI] [PubMed] [Google Scholar]
  25. Snider D. E., Jr, Caras G. J., Koplan J. P. Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. JAMA. 1986 Mar 28;255(12):1579–1583. [PubMed] [Google Scholar]
  26. Snider D. E., Jr, Farer L. S. Preventive therapy for tuberculous infection: an intervention in need of improvement. Am Rev Respir Dis. 1984 Sep;130(3):355–356. doi: 10.1164/arrd.1984.130.3.355. [DOI] [PubMed] [Google Scholar]
  27. Stead W. W., Senner J. W., Reddick W. T., Lofgren J. P. Racial differences in susceptibility to infection by Mycobacterium tuberculosis. N Engl J Med. 1990 Feb 15;322(7):422–427. doi: 10.1056/NEJM199002153220702. [DOI] [PubMed] [Google Scholar]
  28. Stead W. W., To T., Harrison R. W., Abraham J. H., 3rd Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons. Ann Intern Med. 1987 Dec;107(6):843–845. doi: 10.7326/0003-4819-107-6-843. [DOI] [PubMed] [Google Scholar]
  29. Sunderam G., McDonald R. J., Maniatis T., Oleske J., Kapila R., Reichman L. B. Tuberculosis as a manifestation of the acquired immunodeficiency syndrome (AIDS). JAMA. 1986 Jul 18;256(3):362–366. [PubMed] [Google Scholar]
  30. Theuer C. P., Hopewell P. C., Elias D., Schecter G. F., Rutherford G. W., Chaisson R. E. Human immunodeficiency virus infection in tuberculosis patients. J Infect Dis. 1990 Jul;162(1):8–12. doi: 10.1093/infdis/162.1.8. [DOI] [PubMed] [Google Scholar]
  31. Van Scoy R. E., Wilkowske C. J. Antituberculous agents. Isoniazid, rifampin, streptomycin, ethambutol, and pyrazinamide. Mayo Clin Proc. 1983 Apr;58(4):233–240. [PubMed] [Google Scholar]
  32. Vieira J., Frank E., Spira T. J., Landesman S. H. Acquired immune deficiency in Haitians: opportunistic infections in previously healthy Haitian immigrants. N Engl J Med. 1983 Jan 20;308(3):125–129. doi: 10.1056/NEJM198301203080303. [DOI] [PubMed] [Google Scholar]
  33. Weir M. R., Thornton G. F. Extrapulmonary tuberculosis. Experience of a community hospital and review of the literature. Am J Med. 1985 Oct;79(4):467–478. doi: 10.1016/0002-9343(85)90034-8. [DOI] [PubMed] [Google Scholar]
  34. Williams D. M., Krick J. A., Remington J. S. Pulmonary infection in the compromised host. Part II. Am Rev Respir Dis. 1976 Sep;114(3):593–627. doi: 10.1164/arrd.1976.114.3.593. [DOI] [PubMed] [Google Scholar]

Articles from The Yale Journal of Biology and Medicine are provided here courtesy of Yale Journal of Biology and Medicine

RESOURCES